Show simple item record

dc.contributor.authorVargas Soria, María 
dc.contributor.authorCarranza Naval, María José 
dc.contributor.authorMarco Delgado, Ángel José del 
dc.contributor.authorGarcía Alloza, Mónica 
dc.contributor.otherBiomedicina, Biotecnología y Salud Públicaes_ES
dc.date.accessioned2021-09-08T11:06:45Z
dc.date.available2021-09-08T11:06:45Z
dc.date.issued2021-06
dc.identifier.issn1758-9193
dc.identifier.urihttp://hdl.handle.net/10498/25319
dc.description.abstractBackground The described relationship between Alzheimer's disease (AD) and type 2 diabetes (T2D) and the fact that AD has no succesful treatment has led to the study of antidiabetic drugs that may limit or slow down AD pathology. Main body Although T2D treatment has evident limitations, options are increasing including glucagon-like peptide 1 analogs. Among these, liraglutide (LRGT) is commonly used by T2D patients to improve beta cell function and suppress glucagon to restore normoglycaemia. Interestingly, LRGT also counterbalances altered brain metabolism and has anti-inflammatory properties. Previous studies have reported its capacity to reduce AD pathology, including amyloid production and deposition, tau hyperphosphorylation, or neuronal and synaptic loss in animal models of AD, accompanied by cognitive improvement. Given the beneficial effects of LRGT at central level, studies in patients have been carried out, showing modest beneficial effects. At present, the ELAD trial (Evaluating Liraglutide in Alzheimer's Disease NCT01843075) is an ongoing phase IIb study in patients with mild AD. In this minireview, we resume the outcomes of LRGT treatment in preclinical models of AD as well as the available results in patients up to date. Conclusion The effects of LRGT on animal models show significant benefits in AD pathology and cognitive impairment. While studies in patients are limited, ongoing clinical trials will probably provide more definitive conclusions on the role of LRGT in AD patients.es_ES
dc.formatapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherBMCes_ES
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourceAlz Res Therapy 13, 112 (2021)es_ES
dc.subjectLiraglutidees_ES
dc.subjectAlzheimer’s diseasees_ES
dc.subjectAmyloides_ES
dc.subjectTaues_ES
dc.subjectInflammationes_ES
dc.subjectCognitiones_ES
dc.titleRole of liraglutide in Alzheimer's disease pathologyes_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.1186/s13195-021-00853-0


Files in this item

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This work is under a Creative Commons License Atribución 4.0 Internacional